After a cancer diagnosis, a person's identity may change. Often, one may choose to identify with familiar cancer terminology such as "patient," "survivor," or even "victim." These identities can form a lasting positive or negative impact on a person's life.
A lymphoma expert discusses implant removal, reconstruction and the signs of anaplastic large cell lymphoma.
Here are the top 5 CURE stories for July 2019.
The earlier lung cancer is detected, the better chance a person has of surviving the disease. Knowing the risk factors and statistics will help you to understand how you can minimize your possibility of developing the disease.
Following the Food and Drug Administration’s approval of Nubeqa, men with non-metastatic castration-resistant prostate cancer now have an earlier more precise treatment option.
Those of us who live with cancer don't just hope for the good reports, clear scans or positive lab results.
We may be halfway through the summer, but our #CURESummerSnacktime series is just heating up – or cooling down – with this week’s recipe for Dark Chocolate Frozen Banana Bites!
The Food and Drug Administration has approved Keytruda for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus in certain patients.
The Food and Drug Administration granted a priority review to Nubeqa for the treatment of men with non-metastatic castration-resistant prostate cancer.
Here is a list of the recent trial initiations that occurred within the cancer space in July.
Losing both my parents when I was so young led me to what would become my life’s purpose. Advocating for patients with cancer became my motivation and my mission.
Is it possible to be addicted to the anxiety cancer brings? I have been living with that addiction for years but have three ways to combat an anxiety addiction.
CURE® spoke with one expert about the various treatment options and current clinical trials available to patients with mesothelioma, as well as what they have to look forward to in the future.
Since my diagnosis I have gone out of my way to enjoy life in any way possible.
A beloved tradition at a local hospital disappears.
From landmark Senate legislation to the Pink Lemonade Stand Challenge, here’s what is making headlines in the cancer space this week.
CURE spoke with one expert about mesothelioma symptoms that patients can be on the lookout for, as well as how to be knowledgeable about certain risk factors.
One advocacy organization looks beyond just the medical needs of patients to offer support to the "whole patient."
GO2 Foundation will recognize Prof. Peters at the 20th International Lung Cancer Congress for her leadership in lung cancer research.
GO2 Foundation will recognize Prof. Peters at the 20th International Lung Cancer Congress for her leadership in lung cancer research.
The Food and Drug Administration granted a priority review to a new drug application for the accelerated approval of tazemetostat to treat metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.
After a cancer diagnosis, it's common for a person to be presented with many choices regarding health care. As each choice is presented, the person with cancer must make decisions based on the information received. Not all choices are beneficial and should be weighed carefully. Each person has a right to do cancer the way he or she sees fit.
The 13th annual Rhode Island Cancer Summit will host three keynote speakers who plan to focus on gynecologic cancers and cancer in the LGBTQ community.
The Food and Drug Administration has requested that the manufacturer voluntarily recall certain breast implants and tissue expanders from the market to protect women from risks such as breast implant-associated anaplastic large cell lymphoma.
A cancer survivor tells readers how we can warm people up with a small spark even when we do not feel well.
This week on #CURESummerSnacktime, we’ve got a recipe for Middle Eastern Yogurt Dip with Beets: a healthy, quick and easy snack that would be great to serve with baked pitas or vegetables!
With the Food and Drug Administration’s approval of Ruxience, a biosimilar to Rituxan, patients with certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia may have improved access to a more affordable treatment option.
Curaleaf, a Massachusetts-based marijuana producer and retailer, is accused of more than a dozen unfounded claims regarding its products containing cannabidiol.
The Food and Drug Administration approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for the treatment of certain adult patients with CD20-positive B-cell non-Hodgkin’s lymphoma and those with chronic lymphocytic leukemia.
How an app gives a glimpse into the future for many patients with cancer and survivors who fear they won't make it to old age.
